Zacks Investment Research
26 Oct 2026, 16:46 UTC · 5h ago
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Impact · against what's priced in
TNGX faces negative pressure as clinical data for its lead pancreatic cancer program shows a decline in objective response rate and the company implements workforce cuts to preserve cash. While durability data remains strong, the reduction in efficacy and pipeline narrowing suggest a higher risk profile for future pivotal trials.
- TNGX−0.50
No priced-in read yet
- In context
The objective response rate for vopimetostat plus daraxonrasib dropped to 82% from 92%, while a 14% workforce reduction indicates a strategic shift toward cash preservation and a narrowed focus on PRMT5 programs.
Read from the article alone
